Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Filings indexed 1,390 across all filing types
Latest filing 2021-06-21 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 242.3KB
Regulatory Filings
2021-06-21 English
Change in substantial holding 4 pages 90.5KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and references the Corporations Act 2001, Section 671B, which pertains to notices of change of interests of substantial holders. The content details changes in voting power, securities held, and transactions (buy/sell) by a substantial holder, Regal Funds Management Pty Ltd, in the company Opthea Ltd. This type of filing is a notification of changes in significant share ownership levels, consistent with the definition of Major Shareholding Notification (MRQ). The document is detailed and contains specific shareholding changes, not just an announcement or summary, confirming it is the actual notification form.
2021-06-21 English
Proposed issue of securities - OPT 5 pages 27.1KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Opthea Limited regarding a proposed issue of securities, specifically a placement or other type of issue. It includes details such as the number of securities to be issued, the issue date, and compliance with ASX Listing Rules. The content focuses on the announcement of the proposed securities issuance rather than the issuance itself or detailed financial data. The document is about capital raising activities and changes in capital structure, fitting the Capital/Financing Update category. The document length is 5602 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-06-20 English
Change in substantial holding 10 pages 321.3KB
Regulatory Filings
2021-06-20 English
6-K
Regulatory Filings
2021-06-14 English
Opthea Appoints Company Secretary and VP of Finance 2 pages 87.3KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of a new Company Secretary and Vice President of Finance at Opthea Limited. It contains no financial statements, no discussion of financial results, no voting results, no legal proceedings, no capital changes, and no other regulatory filings. It is a management announcement about a personnel change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is 6286 characters, which is sufficient for a detailed announcement but does not contain financial data or other report content. Hence, the classification is MANG with high confidence.
2021-06-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.